^
Association details:
| Biomarker: | RET fusion |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | zeteletinib (BOS-172738) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.
Published date:
05/19/2021
Excerpt:
…67 patients with RET-altered advanced solid tumors received once-daily oral doses of BOS172738 (10-150 mg)….one patient with RET fusion+ pancreatic cancer reported a partial response.
DOI:
10.1200/JCO.2021.39.15_suppl.3008
Trial ID:
